Close Menu

NEW YORK — The US Food and Drug Administration on Monday granted separate Emergency Use Authorizations for SARS-CoV-2 antibody tests developed by TBG Biotechnology and the University of Arizona.

The TBG SARS-CoV-2 IgG/IgM Rapid Test Kit is a lateral flow immunoassay designed to detect and differentiate immunoglobulin G and M antibodies against the virus in serum and plasma. Results are provided in 15 to 20 minutes, according to Melbourne, Australia-based TBG.

The test may be used by any lab certified to perform moderate- or high-complexity tests, the FDA said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.